# 2025年12月3日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 脑出血手术治疗：新证据与观念转变

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41327234](https://pubmed.ncbi.nlm.nih.gov/41327234)
**期刊：** Critical care (London, England)
**PMID：** 41327234
**DOI：** 10.1186/s13054-025-05763-3

### 第一部分 原文与翻译

**英文原标题：** Surgery for intracerebral hemorrhage: new evidence and changing perspectives.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要可用。

### 第二部分 AI 大师评价

本研究旨在综述脑出血手术治疗领域的最新证据与观念演变。作为一篇发表在重症监护领域权威期刊上的综述性文章，本文系统梳理了脑出血手术治疗的最新临床研究进展，探讨了手术干预策略的演变趋势。该研究具有重要的临床指导价值，为神经外科医生和重症监护医师提供了基于最新证据的治疗决策参考，有助于推动脑出血治疗方案的优化与个体化选择。然而，作为综述性文献，其价值主要在于整合现有证据而非提供原始研究数据，未来仍需更多高质量随机对照试验来进一步明确不同手术方式的适应症与疗效。

---

## 2. 肌酐与胱抑素C估算肾小球滤过率的不一致性及其临床结局：一项荟萃分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41202182](https://pubmed.ncbi.nlm.nih.gov/41202182)
**期刊：** JAMA
**PMID：** 41202182
**DOI：** 10.1001/jama.2025.17578

### 第一部分 原文与翻译

**英文原标题：** Discordance in Creatinine- and Cystatin C-Based eGFR and Clinical Outcomes: A Meta-Analysis.

**英文摘要原文：**
IMPORTANCE: Estimated glomerular filtration rates (eGFRs) can differ according to whether creatinine or cystatin C is used for the eGFR calculation, but the prevalence and importance of these differences remain unclear.

OBJECTIVES: To evaluate the prevalence of a discordance between cystatin C-based eGFR (eGFRcys) and creatinine-based eGFR (eGFRcr), identify characteristics associated with greater discordance, and evaluate associations of discordance with adverse outcomes.

DATA SOURCES: Participants in the Chronic Kidney Disease Prognosis Consortium (CKD-PC).

STUDY SELECTION: Participants with concurrent cystatin C and creatinine measurements and clinical outcome measurement.

DATA EXTRACTION AND SYNTHESIS: Between April 2024 and August 2025, data were synthesized using individual-level meta-analysis.

MAIN OUTCOMES AND MEASURES: The primary independent measurement was a large negative eGFR difference (eGFRdiff), defined as an eGFRcys that was at least 30% lower than eGFRcr. Secondary (dependent) outcomes included all-cause and cardiovascular mortality, atherosclerotic cardiovascular disease, heart failure, and kidney failure with replacement therapy.

RESULTS: A total of 821 327 individuals from 23 outpatient cohorts (mean [SD] age, 59 [12] years; 48% female; 13.5% with diabetes; 40% with hypertension) and 39 639 individuals from 2 inpatient cohorts (mean [SD] age, 67 [16] years; 31% female; 30% with diabetes; 72% with hypertension) were included. Among outpatient participants, 11% had a large negative eGFRdiff (range, 3%-50%). Among inpatients, 35% had a large negative eGFRdiff. Among outpatient participants, at a mean (SD) follow-up of 11 (4) years, a large negative eGFRdiff, compared with an eGFRdiff between -30% and 30%, was associated with higher rates of all-cause mortality (28.4 vs 16.8 per 1000 person-years [PY]; hazard ratio [HR], 1.69 [95% CI, 1.57-1.82]), cardiovascular mortality (6.1 vs 3.8 per 1000 PY; HR, 1.61 [95% CI, 1.48-1.76]), atherosclerotic cardiovascular disease (13.3 vs 9.8 per 1000 PY; HR, 1.35 [95% CI, 1.27-1.44]), heart failure (13.2 vs 8.6 per 1000 PY; HR, 1.54 [95% CI, 1.40-1.68]), and kidney failure with replacement therapy (2.7 vs 2.1 per 1000 PY; HR, 1.29 [95% CI, 1.13-1.47]).

CONCLUSIONS AND RELEVANCE: In the CKD-PC, 11% of outpatient participants and 35% of hospitalized patients had an eGFRcys that was at least 30% lower than their eGFRcr. In the outpatient setting, presence of eGFRcys at least 30% lower than eGFRcr was associated with significantly higher rates of all-cause mortality, cardiovascular events, and kidney failure.

**中文摘要译文：**
重要性：根据计算肾小球滤过率（eGFR）时使用的是肌酐还是胱抑素C，估算的肾小球滤过率可能存在差异，但这些差异的发生率及其重要性尚不清楚。

目的：评估胱抑素C估算肾小球滤过率（eGFRcys）与肌酐估算肾小球滤过率（eGFRcr）之间不一致性的发生率，识别与较大不一致性相关的特征，并评估不一致性与不良结局的关联。

数据来源：慢性肾脏病预后联盟（CKD-PC）的参与者。

研究选择：同时具有胱抑素C和肌酐测量值以及临床结局测量的参与者。

数据提取与综合：2024年4月至2025年8月期间，使用个体水平荟萃分析对数据进行综合。

主要结局指标：主要独立测量指标是较大的负性eGFR差异（eGFRdiff），定义为eGFRcys比eGFRcr至少低30%。次要（依赖）结局包括全因死亡率和心血管死亡率、动脉粥样硬化性心血管疾病、心力衰竭以及需要替代治疗的肾衰竭。

结果：共纳入来自23个门诊队列的821,327名个体（平均[SD]年龄59[12]岁；48%为女性；13.5%患有糖尿病；40%患有高血压）以及来自2个住院队列的39,639名个体（平均[SD]年龄67[16]岁；31%为女性；30%患有糖尿病；72%患有高血压）。在门诊参与者中，11%存在较大的负性eGFRdiff（范围：3%-50%）。在住院患者中，35%存在较大的负性eGFRdiff。在门诊参与者中，平均（SD）随访11（4）年后，与eGFRdiff在-30%至30%之间相比，较大的负性eGFRdiff与更高的全因死亡率（28.4 vs 16.8每1000人年[PY]；风险比[HR]，1.69[95% CI，1.57-1.82]）、心血管死亡率（6.1 vs 3.8每1000 PY；HR，1.61[95% CI，1.48-1.76]）、动脉粥样硬化性心血管疾病（13.3 vs 9.8每1000 PY；HR，1.35[95% CI，1.27-1.44]）、心力衰竭（13.2 vs 8.6每1000 PY；HR，1.54[95% CI，1.40-1.68]）以及需要替代治疗的肾衰竭（2.7 vs 2.1每1000 PY；HR，1.29[95% CI，1.13-1.47]）发生率相关。

结论与相关性：在CKD-PC中，11%的门诊参与者和35%的住院患者的eGFRcys比其eGFRcr至少低30%。在门诊环境中，eGFRcys比eGFRcr至少低30%的存在与显著更高的全因死亡率、心血管事件和肾衰竭发生率相关。

### 第二部分 AI 大师评价

本研究通过慢性肾脏病预后联盟的大规模数据，系统评估了肌酐与胱抑素C估算肾小球滤过率不一致性的发生率及其临床意义。研究采用个体水平荟萃分析方法，纳入了超过86万参与者，发现约11%门诊患者和35%住院患者存在显著不一致性（eGFRcys比eGFRcr低30%以上）。创新性地揭示了这种不一致性与全因死亡率、心血管事件及肾衰竭风险显著增加相关，为临床实践中eGFR测量方法的选择和结果解读提供了重要依据。研究局限性在于主要基于观察性数据，未来需要更多机制性研究来阐明不一致性的生物学基础及其与不良结局的因果关系。

---

## 3. 接受重大腹部手术患者个体化围手术期血压管理：IMPROVE-multi随机临床试验

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41076588](https://pubmed.ncbi.nlm.nih.gov/41076588)
**期刊：** JAMA
**PMID：** 41076588
**DOI：** 10.1001/jama.2025.17235

### 第一部分 原文与翻译

**英文原标题：** Individualized Perioperative Blood Pressure Management in Patients Undergoing Major Abdominal Surgery: The IMPROVE-multi Randomized Clinical Trial.

**英文摘要原文：**
IMPORTANCE: Intraoperative hypotension is associated with organ injury. However, it remains unknown if targeted blood pressure management during surgery can improve clinical outcomes.

OBJECTIVE: To evaluate whether individualized vs routine perioperative blood pressure management during major abdominal surgery improves clinical outcomes in patients considered at high risk of postoperative complications.

DESIGN, SETTING, AND PARTICIPANTS: This randomized single-blind clinical trial enrolled patients 45 years or older undergoing elective major abdominal surgery with general anesthesia expected to last 90 minutes or longer who had at least 1 additional high-risk criterion between February 26, 2023, and April 25, 2024, at 15 German university hospitals. The date of last follow-up was July 25, 2024.

INTERVENTION: Patients were randomized in a 1:1 ratio to individualized perioperative blood pressure management (with mean arterial pressure [MAP] targets based on preoperative mean nighttime MAP assessed using automated blood pressure monitoring) or routine blood pressure management with a MAP target of 65 mm Hg or higher.

MAIN OUTCOMES AND MEASURES: The primary outcome was the incidence of a composite outcome of acute kidney injury, acute myocardial injury, nonfatal cardiac arrest, or death within the first 7 postoperative days. There were 22 secondary outcomes, including infectious complications within the first 7 postoperative days and a composite outcome of need for kidney replacement therapy, myocardial infarction, nonfatal cardiac arrest, or death within 90 days after surgery.

RESULTS: Of the 1272 patients enrolled, 1142 were randomized (571 patients to each group), and 1134 were included in the primary analysis (median age, 66 years [IQR, 59-73 years]; 34.1% female). The primary outcome occurred in 190 of 567 patients (33.5%) assigned to individualized blood pressure management and 173 of 567 patients (30.5%) assigned to routine blood pressure management (relative risk, 1.10 [95% CI, 0.93-1.30]; P = .31). None of the 22 secondary outcomes were significantly different, including infectious complications within the first 7 postoperative days (90/567 [15.9%] vs 97/567 [17.1%]; P = .63) and a composite outcome of need for kidney replacement therapy, myocardial infarction, nonfatal cardiac arrest, or death within 90 days after surgery (32/566 [5.7%] vs 20/567 [3.5%]; P = .12).

CONCLUSIONS AND RELEVANCE: Among patients at high risk of postoperative complications undergoing major abdominal surgery, individualized perioperative blood pressure management with MAP targets based on preoperative mean nighttime MAP did not decrease the composite outcome of acute kidney injury, acute myocardial injury, nonfatal cardiac arrest, or death within the first 7 postoperative days compared with routine blood pressure management with a MAP target of 65 mm Hg or higher.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05416944.

**中文摘要译文：**
重要性：术中低血压与器官损伤相关。然而，目前尚不清楚手术期间有针对性的血压管理是否能改善临床结局。

目的：评估在接受重大腹部手术且被认为术后并发症高风险的患者中，个体化与常规围手术期血压管理是否能改善临床结局。

设计、设置和参与者：这项随机单盲临床试验纳入了2023年2月26日至2024年4月25日在15家德国大学医院接受择期重大腹部手术、全身麻醉预计持续90分钟或更长时间、年龄45岁或以上且至少具有1项额外高风险标准的患者。末次随访日期为2024年7月25日。

干预：患者按1:1比例随机分配至个体化围手术期血压管理组（基于术前平均夜间平均动脉压[使用自动血压监测评估]设定平均动脉压目标）或常规血压管理组（平均动脉压目标为65 mm Hg或更高）。

主要结局和指标：主要结局是术后前7天内发生急性肾损伤、急性心肌损伤、非致命性心脏骤停或死亡的复合结局发生率。共有22项次要结局，包括术后前7天内的感染性并发症，以及术后90天内需要肾脏替代治疗、心肌梗死、非致命性心脏骤停或死亡的复合结局。

结果：在入组的1272名患者中，1142名被随机分配（每组571名患者），1134名被纳入主要分析（中位年龄66岁[四分位距59-73岁]；34.1%为女性）。主要结局发生在个体化血压管理组的567名患者中的190名（33.5%）和常规血压管理组的567名患者中的173名（30.5%）（相对风险1.10[95% CI，0.93-1.30]；P=0.31）。22项次要结局均无显著差异，包括术后前7天内的感染性并发症（90/567[15.9%] vs 97/567[17.1%]；P=0.63）以及术后90天内需要肾脏替代治疗、心肌梗死、非致命性心脏骤停或死亡的复合结局（32/566[5.7%] vs 20/567[3.5%]；P=0.12）。

结论和相关性：在接受重大腹部手术且术后并发症高风险的患者中，与平均动脉压目标为65 mm Hg或更高的常规血压管理相比，基于术前平均夜间平均动脉压设定目标的个体化围手术期血压管理并未降低术后前7天内急性肾损伤、急性心肌损伤、非致命性心脏骤停或死亡的复合结局发生率。

试验注册：ClinicalTrials.gov标识符：NCT05416944。

### 第二部分 AI 大师评价

本研究旨在探索基于术前平均夜间平均动脉压的个体化围手术期血压管理策略是否优于常规管理（MAP≥65 mmHg）在降低高风险腹部手术患者术后主要并发症方面。研究采用多中心随机单盲设计，纳入1142例患者，结果显示个体化管理组与常规组在主要复合终点（急性肾损伤、心肌损伤、心脏骤停或死亡）上无显著差异（33.5% vs 30.5%）。该研究的创新性在于将术前夜间血压作为个体化目标设定依据，但阴性结果提示单纯基于夜间血压的个体化策略可能不足以改善临床结局，这为围手术期血压管理研究提供了重要参考，同时也提示未来可能需要更全面的个体化参数或多模态监测策略。

---

速递结束，祝您工作愉快！